ANIX - ITUS (Anixa Biosciences Inc.) ITUS

 ANIXのチャート


 ANIXの企業情報

symbol ANIx
会社名 Anixa Biosciences Inc (ITUS)
分野(sector) Health Care   ヘルスケア
産業(industry) Medical Specialities  
業種 事業サポ―トサ―ビス   医療関連(Health Care)
概要 事業概要 アニーシャ・バイオサイエンス(Anixa Biosciences Inc.)(旧名: ITUS Corporation)腫瘍ベースの癌の早期発見用のCchekという診断プラットフォームの開発に従事する。Cchek癌検出プラットフォームは腫瘍の中および周囲に存在し、血流に入る特定の免疫細胞の存在、不存在および量を検出することによって、悪性腫瘍に対する患者の免疫応答を測定する。身体の免疫系とがん細胞を破壊する能力の変更・強化のかわりに、腫瘍発生時に血流に起こる微妙な免疫的変化を測定する技術とプロトコルを開発する。そのプロトコルを通じて、同社は生検で確認された癌患者の末梢血および健康患者の血液と癌患者の血液を区別するバイオマーカーを検出する。   ITUSは米国の特許技術開発・ライセンス企業。特許技術の開発、取得、ライセンス供与に従事する。同社の特許は、携帯電話やモバイル通信の暗号化、電子書籍用電気泳動ディスプレイ「ePaper」、インタ―ネット電話ゲ―トウェイ、ウェブ会議の暗号化、航空会社などによるロイヤルティ―プログラムのポイント転換システムなどを含む。本社はロサンゼルス。   Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
本社所在地 3150 Almaden Expressway Suite 250 San Jose CA 95118 USA
代表者氏名 Amit Kumar アミットクマール
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 310-484-5200
設立年月日 30256
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 7人
url https://www.anixa.com/
nasdaq_url https://www.nasdaq.com/symbol/anix
adr_tso
EBITDA EBITDA(百万ドル) -9.49194
終値(lastsale) 5.29
時価総額(marketcap) 98902612.34
時価総額 時価総額(百万ドル) 105.07230
売上高 売上高(百万ドル) 1.11250
企業価値(EV) 企業価値(EV)(百万ドル) 99.73120
当期純利益 当期純利益(百万ドル) -10.47935
決算概要 決算概要 BRIEF: For the nine months ended 31 July 2018 Anixa Biosciences Inc revenues increased from $363K to $1.1M. Net loss applicable to common stockholders increased 66% to $8.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in R&D increase from $213K to $2.7M (expense).

 ANIXのテクニカル分析


 ANIXのニュース

   Anixa Biosciences to Present at the 2022 H.C. Wainwright Global Investment Conference  2022/05/05 12:30:00 PR Newswire
SAN JOSE, Calif., May 5, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C. Wainwright Global Investment…
   48 Stocks Moving In Friday''s Mid-Day Session  2022/04/29 16:27:16 Benzinga
Gainers Belite Bio Inc. ADR (NASDAQ: BLTE ) shares surged 144.8% to $14.69. Belite Bio priced its 6 million ADS IPO at $6 per ADS. GTY Technology Holdings Inc. (NASDAQ: GTYH ) shares jumped 116.3% to $6.12 as the company agreed to be acquired by GI Partners. Vaxxinity, Inc. (NASDAQ: VAXX ) surged 63.3% to $6.17. Vaxxinity Executive chairman Lou Reese purchased 22,912 shares at $3.48 per share. Zymeworks Inc. (NYSE: ZYME ) shares climbed 32% to $6.55. Zymeworks confirmed it received an unsolicited, non-binding proposal from All Blue Falcons FZE and its affiliates to purchase the company for $10.50 per share. The Zymeworks board of directors will carefully review the proposal. Finch Therapeutics Group, Inc. (NASDAQ: FNCH ) gained 29.5% to $2.72. The FDA has removed the clinical hold on Finch Therapeutics Group’s investigational new drug application for CP101, an orally administered microbiome therapeutic, which is in Phase 3 study for recurrent C. difficile infection. Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT ) jumped 29.2% to $23.79.
   Anixa Biosciences initiates phase 1 trial of its ovarian cancer CAR-T therapy  2022/03/30 18:30:12 Seeking Alpha
Biotechnology company Anixa Biosciences <> initiated a phase 1 trial evaluating its CAR-T therapy in ovarian cancer.The early-stage trial will be held at Moffitt Cancer Center…
   Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center  2022/03/30 16:45:00 PR Newswire
SAN JOSE, Calif., March 30, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor…
   Anixa says new protease inhibitor outperformed main agent in Pfizer’s COVID-19 pill  2022/01/24 14:06:25 Seeking Alpha
Anixa Biosciences (ANIX) has added ~6.5% in the pre-market after announcing that in early lab studies, a molecule developed by the company and partner MolGenie GmbH was more potent…
   Such Is The Power Of Anixa Biosciences Inc. (NASDAQ: ANIX)  2021/12/08 13:00:00 Stocks Register
Anixa Biosciences Inc. (NASDAQ:ANIX) price closed higher on Tuesday, December 07, jumping 3.35% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy
   Anixa Biosciences Says COVID-19 Compounds Potentially Effective Against Omicron Variant  2021/12/07 17:41:42 Benzinga
Anixa Biosciences Inc (NASDAQ: ANIX ) announced the results of a genomic variant analysis conducted with its partner, MolGenie GmbH , on potential compounds to treat COVID-19. The data indicate that the compounds in development should be effective against the Omicron variant, in addition to the previously identified Delta variant Full story available on Benzinga.com
   Anixa Biosciences Inc. (NASDAQ: ANIX): The Stock For Success Over The Next Few Months  2021/12/07 17:00:00 Marketing Sentinel
In the latest trading session, 0.84 million Anixa Biosciences Inc. (NASDAQ:ANIX) shares changed hands as the companys beta touched 1.75. With the companys most recent per share price at $3.37 changing hands around $0.24 or 7.67% at last look, the market valuation stands at $97.66M. ANIXs current price is a discount, trading about -140.06% off Anixa Biosciences Inc. (NASDAQ: ANIX): The Stock For Success Over The Next Few Months Read More »
   Brokerages Expect Anixa Biosciences, Inc. (NASDAQ:ANIX) Will Announce Earnings of -$0.09 Per Share  2021/12/04 16:36:42 Dakota Financial News
Brokerages expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to announce earnings per share of ($0.09) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Anixa Biosciences earnings. Anixa Biosciences reported earnings per share of ($0.81) in the same quarter last year, which suggests a positive year-over-year growth rate of 88.9%. The business []
   Zacks: Brokerages Expect Anixa Biosciences, Inc. (NASDAQ:ANIX) Will Announce Earnings of -$0.09 Per Share  2021/12/02 11:12:43 Transcript Daily
Wall Street brokerages expect Anixa Biosciences, Inc. (NASDAQ:ANIX) to report earnings of ($0.09) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Anixa Biosciences earnings. Anixa Biosciences reported earnings per share of ($0.81) in the same quarter last year, which would suggest a positive year over year growth rate []
   Anixa Biosciences gets notice of allowance for additional patent on its CAR-T cancer therapy  2021/10/01 12:36:09 Seeking Alpha
   Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy  2021/10/01 12:30:00 PR Newswire
SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of
   Our First Look At Anixa Biosciences  2021/09/23 16:00:27 Seeking Alpha
   Cancer Vaccines Market 2021 Research, Growth and Clinical Analysis - ADAMIS PHARMACEUTICALS CORP., ADVAXIS INC., ALPHAVAX INC., AMGEN INC., Anixa Biosciences Inc  2021/09/08 10:31:11 OpenPR
The report presents an in-depth assessment of the Cancer Vaccines Market including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also
   Anixa Biosciences Says FDA Clears IND For CAR-T Immunotherapy For Ovarian Cancer - Quick Facts  2021/08/30 12:54:50 Business Insider Markets
(RTTNews) - Biotechnology company Anixa Biosciences, Inc. (ANIX) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for its CAR-T (Chimeric Antigen Receptor-T cell) therapy, which is being developed in partnership with Moffitt Cancer Center. The therapeutic product is

 関連キーワード  (事業サポ―トサ―ビス 米国株 ITUS ANIX Anixa Biosciences Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)